PFPaolo Fabris

Paolo Fabris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paolo Fabris has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?

    by M. Milan, S. Boninsegna, L. Scribano, S. Lobello, S. Fagiuoli, P. Fabris, A. Buda, D. Martines

    Pegylated interferon (PEG-IFN) and ribavirin is the most effective treatment for chronic hepatitis C virus (HCV) hepatitis, but the rate of sustained virological response (SVR) remains approximately 50%, and 15–20% of all treated patients have a virological relapse after completing the treatment. Studies on the SVR have failed to discriminate between non-responders and relapsers. To identify the risk factors for relapse among patients with an end-of-treatment response (ETR). We retrospectively analyzed 281 patients consecutively treated with PEG-IFN and ribavirin with a follow-up period of at least 24 weeks. The baseline details collected on each patient included demographic data, histological features, and biochemical profiles. Forty-six patients (16.4%) relapsed during the first 6 months of follow-up after discontinuing the therapy. Relapser patients were significantly older, had more steatosis, fibrosis, and showed significantly lower rapid virological response (RVR) rates compared with SVR patients. By logistic regression analysis, only the absence of RVR was found to be significantly associated with relapses in both subgroups of patients with genotypes 1 and 4 (p < 0.004) and those with genotypes 2 and 3 (p < 0.006). Severe fibrosis was also predictive of relapsing disease, but only for genotypes 2 and 3 patients (p < 0.003). During the treatment, serum HCV-RNA decreased more rapidly in patients with SVR compared to non-responder and relapser patients (p < 0.001). Interestingly, relapser patients exhibited an intermediate serum HCV-RNA decay during the first 4 weeks of therapy. Among HCV patients treated with PEG-IFN and ribavirin, the absence of RVR was the most important independent predictor of relapse, independent of the HCV genotype. In the subgroup of genotypes 2 and 3 patients, the severity of fibrosis was also an important factor associated with the relapse rate.


  • Changing Epidemiology of HCV and HBV Infections in Northern Italy

    by Paolo Fabris, Vincenzo Baldo, Tatjana Baldovin, Emanuela Bellotto, Mario Rassu, Renzo Trivello, Andrea Tramarin, Giulia Tositti, Annarosa Floreani

    To evaluate the hepatitis B virus (HBV) and the hepatitis C virus (HCV) epidemiology in the general population of Northern Italy, a cohort of 965 subjects, all residents (including 47 immigrants), were anonymously tested for HBV and HCV infections. Serum samples were assayed for anti-HCV and anti-HBV markers by enzyme-linked immunosorbent assay and for HCV-RNA by polymerase chain reaction, and the positive cases were genotyped. HBsAg-positive cases were assayed for HBeAg/anti-HBe, whereas HBsAg negatives were tested for both anti-HBc and anti-HBs. The overall prevalence of anti-HCV was 2.6%, with a bimodal distribution characterized by the highest prevalence (12%) in subjects over 75 years old. None of the subjects under 25 years old was anti-HCV positive. Anti-HCV positivity was similar in males and females (2.4% vs. 2.7%). HCV-RNA was positive in 40% of cases and genotype 1 was the most common. The HBsAg prevalence was 1%, with a significant difference according to country of origin (0.8% in Italian subjects vs. 6.4% in immigrants, P=0.01). HBsAg positivity increased significantly with age (R2=0.57, P<0.02). The overall percentages for the prevalence of isolated anti-HBs, anti-HBs+/anti-HBc+, and isolated anti-HBc were 23.8%, 8.4%, and 4.2%, respectively. Our study provides a new picture of HCV and HBV epidemiology in Northern Italy, with these features: (1) a cohort effect showing a reduction of HCV infection in the elderly, possible due to age-related mortality; (2) an unchanged overall prevalence of HBV infection, despite continuing immigration of subjects from endemic countries.


  • Impact of Occult HBV Infection in HIV/HCV Co-Infected Patients: HBVDNA Detection in Liver Specimens and in Serum Samples

    by Paolo Fabris, Maria R. Biasin, Maria T. Giordani, Laura Berardo, Vania Menini, Antonio Carlotto, Maria G. Miotti, Vinicio Manfrin, Vincenzo Baldo, Gaia Nebbia, et al.

    Prevalence and impact of occult HBV infection in HIV positive patients is controversial. The aims of this study were to determine the prevalence of occult HBV infection and its impact on histological and virological parameters. 52 HIV/HCV (but HBsAg-negative) co-infected patients, 29 HBsAg and anti-HCV negative chronic hepatitis, and 20 HBsAg positive chronic hepatitis controls were studied. DNA was extracted from frozen biopsies and amplified with primers for S, C and X regions, and for (ccc) HBV-DNA. Sera were tested for HBV-DNA with two quantitative assays (Cobas Amplicor HBV Monitor, and the real-time COBAS (r) Taqman HBV Test, Roche Diagnostics, UK). Occult HBV infection was detected in 7 (13.4%) liver biopsies of the study group, and in none case of the non viral chronic hepatitis group (p=0.04). All serum samples were HBV-DNA negative with Cobas Amplicor HBV monitor assay, while 3 cases were found positive with real time PCR. Statistical analysis didnt show any impact of occult HBV infection on liver histology, CD4+ cells count, HIV and HCV load, and ALT levels. Occult B infection is relatively frequent in HIV/HCV co-infected patients, and is underestimated by common HBV-DNA serological assays. However, it doesnt seem to exert a relevant impact.


  • Open Access

    Assessing patients’ understanding of hepatitis C virus infection and its impact on their lifestyle

    by P. Fabris, G. Tositti, M. T. Giordani, V. Baldo, A. Grasso, E. Pignattari, S. Canton, S. Rossato, A. Floreani

    Aims To assess how much patients with hepatitis C virus infection know about their condition and what impact it has on their lifestyle. Materials and methods A multiple‐choice questionnaire was administered anonymously to 364 hepatitis C virus‐infected subjects just before their first specialist visit. Results Even before hepatitis C virus infection was diagnosed, 257 subjects (70.6%) already knew something about this infection. Overall, 36% of patients had changed the way they behaved within the family, 25.5% had changed their sexual habits, 46.9% had changed their diet, and 69% reported having stopped or limited their alcohol intake after being told they were hepatitis C virus positive. Hepatitis C virus infection had a negative impact on the psychological status in 44.2% of patients. This effect was significantly greater among women and was independent of either the duration of their infection or any counselling received from the general practitioner. The need for specific treatment was reported by 59.8%. A demand for more detailed information about hepatitis C virus was expressed by 89.9% of patients. Conclusions Hepatitis C virus changes all aspects of lifestyle and psychological status. The patients’ strong demand for more information suggests that counselling and educational programmes must be an integral part of the activities of both the general practitioner and the specialist.


  • Open Access

    Impact of liver steatosis on virological response in elderly Italian patients with chronic hepatitis C treated with peg‐interferon alpha‐2b plus ribavarin

    by P. Fabris, A. Floreani, A. Carlotto, V. Baldo, L. Bozzola, M. T. Giordani, F. Negro, M. Rassu, A. Tramarin, F. de Lalla

    Background : Whether liver steatosis affects sustained virological response in patients with chronic hepatitis C is still under discussion. Aim : To evaluate the impact of liver steatosis in patients treated (for chronic hepatitis C) with combination therapy. Methods : We evaluated 97 (male/female 82/15, mean age 41.1 years) consecutive naïve patients treated with pegylated interferon alpha‐2b plus ribavirin. Results : Prevalence and severity of liver steatosis were significantly associated with genotype 3a [grade 3–4 in 14 of 32 patients (44%) vs. 8 of 65 patients (12%) with other genotypes; P = 0.001], while steatosis grade 1 (P = 0.02]. Overall, sustained virological response was 62.8%, and was statistically uninfluenced by the presence/absence of liver steatosis. On the contrary, the following variables were independently associated with sustained virological response at logistic regression analysis: genotype other than 1a/1b, positive association, (odds ratio 3.4, P < 0.04), and low‐grade liver steatosis, negative association, (odds ratio 9.0, P =0.009), whereas sustained virological response was unaffected by severe liver steatosis, which was mainly associated with genotypes 2 and 3 [steatosis grade 2, 18/29 (62%); grade 3, 10/12 (83%); grade 4, 7/10 (70%)]. Conclusions : Only low‐grade liver steatosis negatively affects the outcome of combination therapy, with peginterferon alpha‐2b plus ribavirin, while severe steatosis (which is virus‐related in most cases) has no impact on virological response.


  • Open Access

    Chlamydia pneumoniae infection in HIV-positive patients: prevalence and relationship with lipid profile

    by G Tositti, M Rassu, P Fabris, Mt Giordani, S Cazzavillan, P Reatto, M Zoppelletto, M Bonoldi, V Baldo, V Manfrin, et al.


  • Open Access

    Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C

    by Paolo Fabris, Annarosa Floreani, Antonio Carlotto, Maria Teresa Giordani, Vincenzo Baldo, Clara Stecca, Lorella Marchioro, Andrea Tramarin, Tosca Bertin, Francesco Negro, et al.


  • Therapy of Chronic Hepatitis C Virus Infection in HIV Co-Infected People

    by P. Fabris, E. Barnes, G. Tositti, M. T. Giordani, A. Grasso, F. Lalla

    Abstract: The introduction of highly active anti-retroviral therapy (HAART) for Human Immunodeficiency Virus (HIV) infection has significantly improved the life expectancy of HIV positive patients. Hepatitis C virus (HCV) co-infection is common in HIV infected patients and is now a significant cause of morbidity and mortality. Optimal management and treatment of HCV in HIV infected patients is therefore essential. Interferon-alpha (IFN-α) and ribavirin is the mainstay of treatment for HCV infection in HIV infected people. The sustained virological response rate (SVR) with combination therapy is lower than that commonly observed in HCV monoinfected patients. This is, at least in part, due to the very high treatment drop out rates. Ribavirin in combination with HAART is associated with particular side effects such as mitochondrial toxicity. Therefore, vigilant monitoring of patients during therapy, in specialist centers is essential. Pegylated interferon (PEG-IFN) plus ribavirin is particularly promising as it is easier to administer and will probably become the treatment of choice for co-infected patients. A SVR is associated with genotype 2 and 3, in addition to a high CD4+ cell count and a low HCV load prior to therapy. The progression of HCV related liver disease in HIV positive patients is faster than in subjects with HCV infection alone. As a result, there is an increasing incidence of cirrhosis and end-stage liver disease in co-infected patients. Liver transplantation is being evaluated in many centers. To date the experiences are very limited but encouraging in term of survival rate.


  • Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C

    by Paolo Fabris, Dave Brown, Giulia Tositti, Loredana Bozzola, Maria Teresa Giordani, Pierantonio Bevilacqua, Fausto de Lalla, George J.M. Webster, Geoffrey Dusheiko


  • Open Access

    Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy

    by P. Fabris, A. Floreani, G. Tositti, D. Vergani, F. De Lalla, C. Betterle

    Type 1 diabetes mellitus is the result of an autoimmune process characterized by pancreatic beta cell destruction. It has been reported that chronic hepatitis C infection is associated with type 2 di...